COMMUNIQUÉS West-GlobeNewswire

R1 Releases Fourth Annual Environmental, Social and Governance (ESG) Report
27/03/2024
Report highlights R1’s commitment to corporate responsibility and sustainability across the company’s global footprint MURRAY, Utah, March 27, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading [...]
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
27/03/2024
- Deep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies of RAF or RAS mutant tumors, both as monotherapy and in combination - - Phase 1 portion of the Phase 1/2a [...]
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
27/03/2024
–PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin– –Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling and ENLIGHTEN-Cirrhosis [...]
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
27/03/2024
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress [...]
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
27/03/2024
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a [...]
Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium
27/03/2024
New Provectus Spinout Company Would Commercialize Combination Therapy of University’s Light Source Medical Device and Provectus’s Pharmaceutical-Grade Rose Bengal Sodium KNOXVILLE, TN, March 27, 2024 (GLOBE NEWSWIRE [...]
One Biosciences Welcomes Dr. Scott Braunstein and Dr. Vincent Miller to its Board of Directors
27/03/2024
Dr. Scott Braunstein, Chairman and CEO of Marinus Pharma and Operating Partner of Aisling Capital; and Dr. Vincent Miller, global expert in cancer, and clinical trial design and interpretation join ahead of One [...]
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
27/03/2024
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet [...]
ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP
27/03/2024
BAUDETTE, Minn., March 27, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Levofloxacin Oral Solution, a generic version of the Reference Listed Drug [...]
26 Patient Volunteer Leaders Attend the Foundation for Sarcoidosis Research Global Sarcoidosis Clinic Alliance Volunteer Patient Leadership Advanced Training Conference held at Cleveland Clinic
27/03/2024
CHICAGO, March 27, 2024 (GLOBE NEWSWIRE) -- 26 Patient Volunteer Leaders representing 16 states and 17 hospitals joined the Foundation for Sarcoidosis Research (FSR) at the inaugural FSR Global Sarcoidosis Clinic [...]
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
27/03/2024
CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies [...]
Zymeworks Announces Participation in Upcoming Investor Conferences
27/03/2024
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve [...]
XORTX Announces New Clinical Advisory Board Member
27/03/2024
CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ) , a biopharmaceutical company focused on developing [...]
Convening of the ordinary general meeting of shareholders of April 26, 2024
27/03/2024
Convening of the Ordinary General Meeting of shareholders of 26 april 2024 The shareholders are invited to attend the ordinary general meeting, which will take place on Friday 26th of April 2024 at 11:00AM, at the [...]
Convocation à l'assemblée générale ordinaire du 26/04/2024
27/03/2024
Convocation à l’Assemblée Générale Ordinaire des actionnaires du 26 avril 2024 Les actionnaires sont invités à prendre part à l’assemblée générale ordinaire qui se tiendra le 26 avril 2024 à 11 heures au siège de la [...]
Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma
27/03/2024
Tokyo, Japan and Cambridge, UK, 27 March 2024 – Sosei Group Corporation (“the Company”; TSE: 4565) announces that the re-election of its Board of Directors and Executive Officers was approved at the Company’s 34th [...]
Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate
27/03/2024
Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate London (UK), March 27, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; [...]
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
27/03/2024
RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET Amsterdam, the [...]
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA
27/03/2024
Pratteln, Switzerland, March 27, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that the China National Medical Products Administration (NMPA) has accepted for priority review the new drug application (NDA) for [...]

Pages